Article info
PDFWhat neurologists need to understand outside their own speciality
Diabetes mellitus: what the neurologists need to know
- Correspondence to Professor Jeffrey Wayne Stephens, Diabetes, Swansea University Medical School, Swansea, Swansea, UK; j.w.stephens{at}swansea.ac.uk
Citation
Diabetes mellitus: what the neurologists need to know
Publication history
- Accepted July 5, 2022
- First published July 30, 2022.
Online issue publication
October 18, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- New advances in type 1 diabetes
- Current management of diabetes mellitus and future directions in care
- Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial)
- Advances in the management of diabetes: new devices for type 1 diabetes
- Novel therapies for diabetes mellitus in pregnancy
- Advances in the management of type 2 diabetes in adults
- Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus
- Diabetic ketoacidosis with SGLT2 inhibitors
- HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment
- Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study